Driven by a shared commitment to advancing responsible, ethical research, Advarra thought leaders will exchange ideas and foster collaboration across several initiatives
Columbia, Md. – Oct. 23, 2025 – Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced its extended participation in this year’s PRIM&R conference, taking place November 6–8 in Baltimore, MD.
For nearly five decades, PRIM&R has been the premier forum for advancing the ethical conduct of clinical research and addressing the evolving challenges faced by Human Research Protection Program (HRPP) professionals at sites and institutions. Advarra has proudly participated in the PRIM&R conference for decades, joining the conversation to collaborate with peers, exchange insights, and help move the field forward.
This year, Advarra will showcase seven dedicated presentations, highlighting the expertise of six of its leading subject matter experts in research ethics, compliance, and operations. Attendees can also connect with Advarra at Booth #201 to engage in meaningful discussions and explore how the company’s technology and services help simplify oversight while upholding the highest ethical standards.
The following will be presented:
- Jan Hewett, SVP, FDA Regulatory Advisor – “Sponsored Session: Demystifying the Reporting of Unanticipated Problems and Serious/Continuing Noncompliance to Federal Agencies for IRB Professionals” | Nov. 8, 12:30–1:30 p.m. ET
- Faith Bertrand, Associate Director, Institutional Research Center of Excellence – “SBER and Biomedical IRBs: Opportunities for Shared Learning” | Nov. 6, 10:15–11:15 a.m. ET
- Erin Odor, IRB Chairperson – “When SBER Meets FDA: A Survival Guide to Support SBE IRBs and Researchers” | Nov. 6, 11:30 a.m.–12:30 p.m. ET
- Julie Ozier, SVP & IO, Regulatory – “Proactive Strategies for Emerging Trends and Crisis Management” | Nov. 7, 10:30–11:45 a.m. ET
- Josh Fedewa, Managing Director, Consulting – “Plenary: Continuing the Mission: Conducting Ethical Research and Good Science in the Face of Pressure” | Nov. 8, 10:30–11:45 a.m. ET
- Luke Gelinas, Senior Chair Director
- “Plenary: What Counts as a Direct Benefit of Research?” | Nov. 8, 10:30–11:45 a.m. ET
- “Round Table Discussion: Should We Still Be Using Unconsented Biospecimens for Research in 2025?” | Nov. 8, 12:30–1:30 p.m. ET
“At Advarra, we’re deeply committed to understanding our clients—their realities, their goals, and the pressures and constraints they face in advancing ethical research,” said Lauri Carlile, chief research services officer at Advarra. “We’ve long admired PRIM&R’s dedication to protecting research participants and fostering collaboration across the research community, and we’re excited to continue exchanging ideas and learning from peers who share our passion for this work.”
Beyond its speaking sessions, Advarra will offer a variety of opportunities for attendees to connect and engage throughout the conference, including:
- Hosting “Homerun Connections at PRIM&R: A Night at Oriole Park,” an exclusive gathering of leaders and innovators across the industry for networking, conversation, and a unique ballpark experience. Nov. 7, 7–9 p.m. ET, Oriole Park at Camden Yards.
- Providing complimentary cookies at Advarra Booth #201.
- Sponsoring and participating in the Expo Center Scavenger Hunt.
As the industry’s leading central IRB, Advarra reviews twice as many studies as any other IRB—serving as a trusted partner to more than 3,500 sites and institutions across the research landscape. To learn more, schedule a meeting on-site, and RSVP for Advarra’s networking event, visit https://resource.advarra.com/primr-2025.
About Advarra
Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions improve collaboration, transparency, and compliance to optimize study design and operations. With unmatched trial operations data, and an ongoing investment in AI innovation, Advarra continues to reimagine what’s possible in clinical research. For more information, visit advarra.com.
Media Contact:
Michelle Valentine
michellevalentinepr@outlook.com / mediarelations@advarra.com